A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previously Treated with Standard of Care Therapy. - ARTEMIDEsubQ

Study identifier:D702EC00001

ClinicalTrials.gov identifier:NCT07161414

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previously Treated with Standard of Care Therapy (ARTEMIDE-subQ)

Medical condition

Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma

Phase

Phase 1

Healthy volunteers

no

Study drug

Rilvegostomig, Recombinant Human Hyaluronidase, IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig, SC rilvegostomig + rHu

Sex

All

Estimated Enrollment

40

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 20 Jul 2027
Estimated Primary Completion Date: 19 Aug 2028
Estimated Study Completion Date: 03 Jul 2029

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2027 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria